Logos Global Management’s Day One Biopharmaceuticals DAWN Stock Holding History

Logos Global Management’s Portfolio DAWN Stock Details DAWN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-300,000	Closed	-$2.8M	–	70
2025 Q4	$2.8M	Buy	+300,000	New	+$2.51M	0.17%	59
2023 Q3	–	Sell	-650,000	Closed	-$7.76M	–	63
2023 Q2	$7.76M	Buy	+650,000	New	+$8.49M	1.06%	29
2022 Q1	–	Sell	-37,069	Closed	-$624K	–	51
2021 Q4	$624K	Sell	37,069 -15,000	-29%	-$308K	0.06%	63
2021 Q3	$2.8M	Buy	52,069 +15,000	+40%	+$359K	0.2%	47
2021 Q2	$844K	Buy	+37,069	New	+$773K	0.07%	55

Other funds holding DAWN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

Kryger Capital London, United Kingdom $1.41B AUM 86.31% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return

Logos Global Management's DAWN Position: Q1 2026 in Review

Logos Global Management sold out of Day One Biopharmaceuticals (DAWN) in Q1 2026, closing a stake of 300,000 shares — an estimated $2.8M sold.

Logos Global Management first reported a position in DAWN in Q2 2021 and held it in 5 quarters. The position peaked at $7.76M in Q2 2023. 206 funds tracked by Wall St. Rank hold DAWN as of Q1 2026.

Logos Global Management reported no remaining Day One Biopharmaceuticals position as of Q1 2026 after selling out during the quarter.
Logos Global Management sold 300,000 Day One Biopharmaceuticals shares in Q1 2026, an estimated $2.8M.
Logos Global Management first reported a position in Day One Biopharmaceuticals in Q2 2021 and held it in 5 quarters.
Logos Global Management's Day One Biopharmaceuticals position peaked at $7.76M in Q2 2023.
206 funds tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q1 2026.

Based on Logos Global Management's 13F filing for Q1 2026, filed 15 May 2026.